Impact of stopping burosumab treatment at the end of skeletal growth in adolescents with X-linked hypophosphatemia (XLH).

Jarvis, C.; Ramakrishnan, R.; Dharmaraj, P.; Mushtaq, T.; Gupta, S.; Williams, A.; Rylands, AJ.; Barham, H.; Nixon, A.; Uday, S.

Impact of stopping burosumab treatment at the end of skeletal growth in adolescents with X-linked hypophosphatemia (XLH).

All Authors

Jarvis, C.

Ramakrishnan, R.

Dharmaraj, P.

Mushtaq, T.

Gupta, S.

Williams, A.

Rylands, AJ.

Barham, H.

Nixon, A.

Uday, S.

LTHT Author

Mushtaq, Talat

LTHT Department

Leeds Children's Hospital
Children's Endocrinology

Publication Date

2025

Item Type

Case Reports
Journal Article

Abstract

Many adolescents with X-linked hypophosphatemia (XLH) currently have to stop treatment with burosumab at the end of skeletal growth. We describe the experience of a cohort of adolescents with XLH before, during, and after stopping burosumab (median treatment duration 37.5 months). Improvements in serum phosphate, pain, mobility, function, and quality of life noted during burosumab treatment were reversed after treatment cessation. Further real-world data are needed to explore the value of uninterrupted burosumab treatment in adolescents.